Equities researchers at MLV Capital increased their target price on shares of Geron Corp. (NASDAQ:GERN) from $8.00 to $9.00 in a research report issued on Tuesday, Analyst Ratings.Net reports. The firm currently has a “buy” rating on the stock. MLV Capital’s target price would suggest a potential upside of 63.04% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Needham & Company upgraded shares of Geron Corp. from a “hold” rating to a “buy” rating in a research note to investors on Tuesday. They now have a $10.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Geron Corp. in a research note to investors on Wednesday, November 13th. They now have a $5.25 price target on the stock. Finally, analysts at Stifel Nicolaus upgraded shares of Geron Corp. from a “sell” rating to a “hold” rating in a research note to investors on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $7.06.
Shares of Geron Corp. (NASDAQ:GERN) opened at 5.52 on Tuesday. Geron Corp. has a 1-year low of $0.98 and a 1-year high of $7.79. The stock has a 50-day moving average of $4.85 and a 200-day moving average of $2.59. The company’s market cap is $711.9 million.
Geron Corp. (NASDAQ:GERN) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.06). The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.49 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was down 71.5% on a year-over-year basis. On average, analysts predict that Geron Corp. will post $-0.29 earnings per share for the current fiscal year.
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company developing therapies for cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.